Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review.

IF 0.5 Q4 ONCOLOGY International Cancer Conference Journal Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI:10.1007/s13691-024-00696-0

Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao

{"title":"Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review.","authors":"Shogo Nishino, Mayu Yunokawa, Yosuke Matsuura, Atsushi Fusegi, Satoki Misaka, Yoichi Aoki, Akiko Abe, Makiko Omi, Hiroyuki Kanao","doi":"10.1007/s13691-024-00696-0","DOIUrl":null,"url":null,"abstract":"<p><p>Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case of a 57-year-old woman with stage IIIB cervical cancer who developed SSP during bevacizumab chemotherapy. Despite complete remission with cisplatin-based chemoradiotherapy, she experienced a recurrence 9 months later. A thoracoscopic surgery was performed to remove a lung nodule and bulla. Subsequently, local cervical lesion recurrence and lung metastases were noted, and paclitaxel and carboplatin combined with bevacizumab were administered. After two cycles, a grade-1 left pneumothorax occurred, attributed to bevacizumab-induced tissue fragility. The patient improved within 7 days with conservative management. Bevacizumab was discontinued, and pneumothorax did not recur. This case highlights the rare occurrence of SSP in patients with cervical cancer treated with bevacizumab and underscores the importance of appropriate management of such patients, especially those who have undergone early thoracic surgery.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464977/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-024-00696-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Secondary spontaneous pneumothorax (SSP) due to bevacizumab has been reported in other malignancies but not in cervical cancer. We present the case of a 57-year-old woman with stage IIIB cervical cancer who developed SSP during bevacizumab chemotherapy. Despite complete remission with cisplatin-based chemoradiotherapy, she experienced a recurrence 9 months later. A thoracoscopic surgery was performed to remove a lung nodule and bulla. Subsequently, local cervical lesion recurrence and lung metastases were noted, and paclitaxel and carboplatin combined with bevacizumab were administered. After two cycles, a grade-1 left pneumothorax occurred, attributed to bevacizumab-induced tissue fragility. The patient improved within 7 days with conservative management. Bevacizumab was discontinued, and pneumothorax did not recur. This case highlights the rare occurrence of SSP in patients with cervical cancer treated with bevacizumab and underscores the importance of appropriate management of such patients, especially those who have undergone early thoracic surgery.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

宫颈癌贝伐单抗化疗期间的继发性自发性气胸：病例报告和文献综述。

贝伐珠单抗引起的继发性自发性气胸（SSP）在其他恶性肿瘤中也有报道，但在宫颈癌中却未见报道。我们报告了一例患有 IIIB 期宫颈癌的 57 岁女性病例，她在贝伐珠单抗化疗期间出现了 SSP。尽管顺铂为基础的化放疗使她的病情完全缓解，但 9 个月后她的病情再次复发。她接受了胸腔镜手术，切除了一个肺结节和肺大泡。随后，她发现宫颈局部病灶复发和肺部转移，于是接受了紫杉醇和卡铂联合贝伐单抗治疗。两个周期后，由于贝伐单抗引起的组织脆性，患者出现了一级左侧气胸。经过保守治疗，患者在 7 天内病情好转。停用贝伐珠单抗后，气胸没有复发。本病例突显了贝伐单抗治疗宫颈癌患者发生 SSP 的罕见性，并强调了对此类患者，尤其是接受过早期胸腔手术的患者进行适当治疗的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)